Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders.
The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs -- either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions -- from depression to chronic pain -- as well as for specific populations and circumstances -- from children and adolescents to psychiatric emergencies -- offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response.
The book's beneficial features are many: The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology. History and discovery, structure--activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug--drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees. Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine). More than 180 tables and graphs present critically important data in an accessible way.
A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.
ContributorsIntroduction Part I: Principles of PharmacologyChapter 1. Basic Principles of Molecular Biology and GenomicsChapter 2. NeurotransmittersChapter 3. GeneticsChapter 4. PsychoneuroendocrinologyChapter 5. Brain--Immune System InteractionsChapter 6. PharmacokineticsChapter 7. Brain Imaging in PsychopharmacologyPart II: Classes of Psychiatric Treatments Antidepressants and AnxiolyticsChapter 8. Monoamine Oxidase InhibitorsChapter 9. TricyclicsChapter 10. FluoxetineChapter 11. SertralineChapter 12. ParoxetineChapter 13. FluvoxamineChapter 14. CitalopramChapter 15. Trazodone and NefazodoneChapter 16. VortioxetineChapter 17. MirtazapineChapter 18. BupropionChapter 19. VenlafaxineChapter 20. Duloxetine, Milnacipran, and LevomilnacipranChapter 21. KetamineChapter 22. BenzodiazepinesChapter 23. BuspironeAntipsychoticsChapter 24. Classic AntipsychoticsChapter 25. ClozapineChapter 26. OlanzapineChapter 27. QuetiapineChapter 28. Risperidone and PaliperidoneChapter 29. AripiprazoleChapter 30. ZiprasidoneChapter 31. AsenapineChapter 32. IloperidoneChapter 33. LurasidoneChapter 34. CariprazineChapter 35. Drugs to Treat Extrapyramidal Side EffectsDrugs for Treatment of Bipolar DisorderChapter 36. LithiumChapter 37. Valproate BowdenChapter 38. CarbamazepineChapter 39. GabapentinChapter 40. LamotrigineChapter 41. TopiramateOther AgentsChapter 42. Agents for Cognitive DisordersChapter 43. Sedative-HypnoticsChapter 44. Psychostimulants and Wakefulness-Promoting AgentsChapter 45. NeurostimulationPart III: Psychopharmacological TreatmentChapter 46. Treatment of DepressionChapter 47. Treatment of Bipolar DisorderChapter 48. Treatment of Anxiety and Related DisordersChapter 49. Treatment of SchizophreniaChapter 50. Treatment of Substance-Related DisordersChapter 51. Treatment of Personality DisordersChapter 52. Treatment of Eating DisordersChapter 53. Treatment of InsomniaChapter 54. Treatment of Chronic PainChapter 55. Treatment of Child and Adolescent DisordersChapter 56. Treatment During Late LifeChapter 57. Psychopharmacology During Pregnancy and LactationChapter 58. Treatment of Psychiatric EmergenciesChapter 59. Treatment of Agitation and Aggression in the Elderly